This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Matthew Thomas Reynolds and His Patent on Orexin Receptor Agonists.
Introduction
Matthew Thomas Reynolds is an inventor associated with Kanagawa, Japan, and Takeda Pharmaceutical Company Limited. His patent work concerns a potential treatment approach for narcolepsy.
Latest Patents
Reynolds is associated with 1 patent: “Macrocyclic heterocycle compounds and use thereof.” The invention describes heterocyclic compounds, or their salts, with orexin type 2 receptor agonist activity. The patent identifies these compounds as potentially useful for the prevention or treatment of narcolepsy.
Career Highlights
Reynolds’s listed patent reflects research into compounds that activate the orexin type 2 receptor, a target relevant to sleep and wakefulness. His company affiliation is Takeda Pharmaceutical Company Limited.
Collaborations
Kohei Takeuchi and Shuhei Ikeda are identified as Reynolds’s coworkers. Their names are associated with the collaborative context of his work on the patent.
Conclusion
Matthew Thomas Reynolds’s patent work at Takeda Pharmaceutical Company Limited focuses on orexin type 2 receptor agonists and their potential application in narcolepsy treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile